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Heart failure is a global health challenge, affecting 1–2% of the 
population and up to an estimated 64 million people worldwide.1,2 In the 
UK, just under 1 million people have heart failure, with approximately 
350 new diagnoses each year per 100,000 population.3 The lifetime 
risk of developing heart failure at 55 years of age is 33% for men and 
28% for women.4 The heart failure population is heterogenous with 17 
aetiologies defined in the Lancet Global Burden of Disease studies.5 
Ischaemic heart disease predominates, accounting for 40–50% of 
cases, with hypertensive and valvular disease accounting for a further 
15%.6,7 About one-third of heart failure patients are labelled as having 
idiopathic dilated cardiomyopathy (DCM). Global studies highlight a 
significantly higher burden of non-ischaemic heart failure outside of 
western Europe and the US.8–10
Patients attending a heart failure clinic undergo a clinical history 
and examination as per clinical practice guidelines. They will have a 
12-lead ECG, echocardiography and serological tests to determine 
full blood count, renal function, thyroid function and selected cardiac 
biomarkers. Patients are classified using left ventricular ejection 
fraction (LVEF) into having heart failure with reduced ejection fraction 
(HFrEF; LVEF <40%), mid-range ejection fraction (HFmrEF; LVEF 40–49%) 
or preserved ejection fraction (HFpEF; LVEF ≥50%).11 For patients with 
a reduced or mid-range EF, further investigation aims to rule out 
ischaemic, valvular and hypertensive heart disease. Where these tests 
are negative, patients are frequently given a diagnosis of idiopathic 
DCM, with emphasis on prompt initiation and uptitration of evidence-
based pharmacological treatment and consideration of device therapy. 
In recent years, this approach has been augmented by improved 
community heart failure services and the introduction of newer 
pharmacological therapies.12–14 However, trends in survival rates have 
shown only a modest improvement, particularly when compared to 
fields such as oncology.15
Current diagnostic strategies fail to identify the presence of rare 
disease in the heart failure population. The EU defines rare disease as 
one that is present in fewer than 1 in 2,000 of the population. However, 
with as many as 8,000 recognised rare diseases, the cumulative 
burden of rare disease affects more than 30 million people in Europe 
alone. Those affected frequently suffer from delays in diagnosis with a 
significant impact on quality of life and, potentially, prognosis.16,17 
Rarer causes of common presentations are seldom considered in 
everyday clinical practice. The diagnostic process often places too 
much emphasis on clinical traits such as LVEF, to the exclusion of a 
more nuanced approach. Traditional rhetoric argues that delineation 
of the idiopathic DCM population is superfluous to their treatment, 
as elucidation of aetiology will not lead to a deviation from standard 
management protocols. Increasingly, it is recognised that identification 
of an underlying genetic, inflammatory or infiltrative cause of heart 
failure can have profound implications for the patient and – where 
hereditary – their relatives.18–20
Genetic Cardiomyopathies
A significant proportion of people with idiopathic DCM have familial 
disease, with estimates typically in the region of 30–50%.21,22 A large 
scale meta-analysis, including 23 studies published from 1980 to 
2010, resulted in a combined prevalence estimate of 23% with a large 
range (2–65%), highlighting significant heterogeneity across studies.21 
The estimated prevalence of familial DCM increased with publication 
year, suggesting that greater awareness and access to screening has 
increased the number of recognised cases. A recent study identified 
Abstract
Current diagnostic strategies fail to illuminate the presence of rare disease in the heart failure population. One-third of heart failure 
patients are categorised as suffering an idiopathic dilated cardiomyopathy, while others are labelled only as heart failure with preserved 
ejection fraction. Those affected frequently suffer from delays in diagnosis, which can have a significant impact on quality of life and 
prognosis. Traditional rhetoric argues that delineation of this patient population is superfluous to treatment, as elucidation of aetiology will 
not lead to a deviation from standard management protocols. This article emphasises the importance of identifying genetic, inflammatory 
and infiltrative causes of heart failure to enable patients to access tailored management strategies.
Keywords
Heart failure, rare disease, dilated cardiomyopathy, genetic cardiomyopathy, myocarditis, cardiac amyloidosis.
Disclosure: The authors have no conflicts of interest to declare.
Received: 22 March 2019 Accepted: 6 June 2019 Citation: European Cardiology Review 2019;14(2):89–96. DOI: https://doi.org/10.15420/ecr.2019.19.2  
Correspondence: Perry Elliott, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6BT, UK. E: perry.elliott@ucl.ac.uk
Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, 
provided the original work is cited correctly.
Hidden in Heart Failure
Douglas Ewan Cannie,1,2 Mohammed Majid Akhtar1,2 and Perry Elliott1,2
1. University College London Institute for Cardiovascular Science, London, UK; 2. Barts Heart Centre, Barts Health NHS Trust, London, UK
90
Heart Failure, Arrhythmias and Cardiomyopathies
E U R O P E A N  C A R D I O L O G Y  R E V I E W
familial disease in 26% of idiopathic DCM patients listed for cardiac 
transplantation.23 
Using these data, we can conservatively estimate that 10% of an 
undifferentiated heart failure population may have familial disease, 
emphasising the importance of a detailed family history.24 This 
has implications for patients and their families and should prompt 
consideration of family screening and genetic testing.25,26 Panel-
based, next-generation sequencing has shown a pathogenic or likely 
pathogenic variant in almost 50% of patients with familial DCM and 
25% in those with sporadic disease.27,28 The yield from genetic testing 
will change with a better understanding of variant pathogenicity and 
the discovery of new disease genes.
Identification of a definite genetic cause can have profound implications 
for the patient and their family (Figure 1). Mutations in the gene coding for 
lamins A and C (LMNA) are well recognised as predictors of a malignant 
clinical course with progressive conduction disease and arrhythmia, even 
where left ventricular systolic impairment is mild.29 Patients with an LMNA 
mutation must be considered for prophylactic ICD implantation at an early 
stage of disease.30 Filamin C (FLNC) mutations are similarly predictive of a 
high risk of arrhythmogenic complications. A recent study has found that 
85% of DCM patients with truncating FLNC variants had either ventricular 
arrhythmias or sudden cardiac death.31,32 Pathogenic variants in SCN5A 
(encoding for the cardiac sodium channel), RMB20 (encoding for the 
RNA binding motif protein 20) and BAG3 (encoding for an antiapoptotic 
protein on the sarcomere Z-disc) have also been identified as carrying an 
increased risk of ventricular arrhythmia or progressive heart failure.33–37 
Myocarditis
Regardless of aetiology, myocardial injury often prompts an 
inflammatory response and cardiac autoantibodies are found in high 
levels in patients with both ischaemic and non-ischaemic end-stage 
heart failure.38–41 However, care should be taken to differentiate between 
cardiac injury leading to inflammation and cardiac dysfunction driven 
by inflammation. The term inflammatory cardiomyopathy has been 
used to describe myocarditis that leads to impaired function. Causes of 
myocarditis are numerous, with viral infection being the most common 
and parvovirus B19, human herpes virus 6 and enteroviruses the most 
frequently implicated.42,43 Bacteria, parasites, protozoa and many toxic 
agents and autoimmune disorders also contribute.44
Histological evidence for myocarditis in patients with DCM and 
heart failure is frequently reported. In a study of 1,278 patients with 
congestive cardiac failure and DCM, 24% had an underlying diagnosis 
confirmed on endomyocardial biopsy that could be attributed to 
an inflammatory cause.45 Inflammatory disease may be particularly 
common in patients with idiopathic DCM and ventricular arrhythmia. 
A study of 103 non-ischaemic cardiomyopathy patients presenting 
with monomorphic or polymorphic ventricular tachycardia, or with 
premature ventricular complexes, found that just under 50% had 
ongoing focal myocardial inflammation on fluorodeoxyglucose PET 
(FDG-PET). Immunosuppressive therapy was associated with an 
improvement in ejection fraction, particularly in those identified at an 
early stage of the disease process. A third of those with a positive scan 
were subsequently diagnosed with sarcoidosis by tissue biopsy.46 
The prevalence of myocarditis remains elusive due to the heterogeneity 
of aetiologies and modes of presentation. In approximately 50% 
of cases, acute myocarditis resolves in 2–4 weeks. However, up 
to 25% develop persistent cardiac dysfunction and 12–25% may 
acutely deteriorate or progress to end-stage DCM.47 Histological 
studies suggest that between 10–52% of patients with acute viral 
myocarditis progress to a DCM and biopsy-based analysis shows that 
viral persistence is associated with progressive LV dysfunction.48–51 
Recent data suggest that more than half of patients presenting with 
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Figure 1: A Case of Breathlessness and Peripheral Oedema
A 66-year-old man presented with a 3-month history of breathlessness and peripheral oedema. He had suffered rheumatic fever as an adolescent and had been told at the time he had 
atrioventricular block and mitral valve changes. His ECG showed left ventricular hypertrophy and a QRS of 134 ms. Transthoracic echocardiography was technically difficult, but demonstrated 
an enlarged heart with severe left ventricular systolic dysfunction and no significant valvular abnormalities. A coronary angiogram showed normal coronary arteries. He was initially managed 
with heart failure medications. Cardiac MRI confirmed a dilated heart with poor systolic function and mid-wall late gadolinium enhancement at the basal anteroseptum and inferior wall (red 
arrows). On subsequent questioning, a thorough family history identified that the patient’s mother had died at a young age with a ‘weak heart’. Other family members had died in childhood 
of causes unknown. Genetic analysis showed a mutation in the filamin C gene. This mutation should prompt early consideration of ICD implantation, clinical screening of first degree relatives 
and cascade genetic screening.
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acute lymphocytic myocarditis and an LVEF <50% suffer persistent 
left ventricular systolic dysfunction.52 Immunohistological analysis 
of biopsy material from patients with chronic DCM shows that 40% 
have evidence of myocardial inflammation.53 The subclinical nature of 
myocardial inflammation is well recognised in children and adults.54–56
That inflammatory cardiomyopathy exists within the heart failure 
population seems irrefutable. Identifying these patients offers the 
opportunity to significantly alter the course of the disease. For 
example, immunosuppression in patients with virus-negative, chronic 
inflammatory cardiomyopathy can result in a mean improvement in LVEF 
from 26% to 46%.57 It also improves rates of transplant-free survival.58 
Independent of virus-status, DCM patients with increased human 
leukocyte antigen (HLA) system expression have also demonstrated 
significant improvements in LVEF with immunosuppression.53 
Systemic Autoimmune Disorders 
Systemic autoimmune disorders frequently affect the heart and 
autoimmunity plays a pivotal role in myocarditis and in DCM.59 Systemic 
lupus erythematosus (SLE) is associated with numerous cardiac 
disorders and carries a high risk of developing myocarditis, with clinical 
detection rates in the region of 3–15%.60 African-American people are 
particularly at risk.61 The inflammatory process is driven by immune 
complex and complement deposition in the myocardium leading to 
cardiac dysfunction, DCM and heart failure. SLE may present with 
myocarditis or with heart failure, which can rapidly progress.62,63 A low 
threshold of suspicion must be maintained, with awareness that cardiac 
biomarkers and ECG results may be normal.64 An echocardiogram may 
demonstrate regional or global ventricular dysfunction, with strain 
techniques offering earlier diagnosis.65 Cardiac MRI can detect subclinical 
inflammation in SLE.66,67 Recommended treatment is corticosteroids and 
immunosuppressive agents such as cyclophosphamide.68 Myocarditis in 
SLE is associated with lower survival rates.61
Rheumatoid arthritis and systemic sclerosis-associated myocarditis are 
diagnosed less frequently. However, cardiac MRI studies of these patient 
populations suggest a high prevalence of myocardial involvement, with 
half of patients demonstrating evidence of myocardial fibrosis with 
late gadolinium enhancement.69,70 Cardiac involvement is found in 
27–47% of patients with eosinophilic granulomatosis with polyangiitis, 
previously called Churg-Strauss syndrome, with myocarditis one of the 
most common cardiac manifestations.71–73 Myocarditis is also seen in 
Behcet’s disease, Takayasu arteritis, dermatomyositis and polymyositis. 
It tends to be associated with poorer outcomes and treatment is with 
steroids and immunosuppression.44,68 
Giant Cell Myocarditis
Giant cell myocarditis is a disease that predominantly affects young 
people. It typically presents with acute heart failure and ventricular 
arrhythmias. Approximately 20% of patients have a pre-existing 
autoimmune disorder and the severe inflammation appears to be 
mediated predominantly by a T-cell response. Early diagnosis is key as 
median survival without transplant or immunosuppression is less than 
3 months.44
Sarcoidosis
Sarcoidosis is an inflammatory, non-caseating granulomatous disease 
affecting multiple organ systems including the skin, eyes, lungs, 
heart and the nervous system. The incidence rate in the US has been 
reported at 10.9 per 100,000 in white people and 35.5 per 100,000 in 
black people.74 Higher incidence rates are reported in people from 
Scandinavia and Japan.75 Cardiac manifestations are seen in only 
2–5% of patients with systemic sarcoidosis but there is a significantly 
higher proportion of subclinical cardiac disease.76,77 At autopsy, cardiac 
involvement was observed in 14% of white people, 21% of black people 
and 68% of Japanese people with sarcoidosis.78 The aetiology is poorly 
understood. Environmental exposures and infectious organisms have 
been implicated and the involvement of genetic factors is supported 
by twin studies and familial clustering.79 
Cardiac sarcoidosis is frequently asymptomatic but may present with 
conduction defects, arrhythmias or heart failure. Clinical clues include 
bilateral hilar lymphadenopathy on chest X-ray and elevated levels of 
serum angiotensin converting enzyme and serum calcium. The ECG 
may highlight conduction defects or repolarisation abnormalities, but 
is abnormal in less than 10% of people with clinically silent disease.74 
An echocardiogram with longitudinal strain parameters is useful in 
identifying cardiac involvement and in predicting major cardiovascular 
events.80,81 Imaging techniques such as FDG-PET and cardiac MRI with 
gadolinium contrast offer a high degree of diagnostic accuracy, but 
diagnostic criteria either fail to recognise the benefits of advanced 
imaging or rely heavily on biopsy results.82–85 
Corticosteroids remain the mainstay of treatment for cardiac 
sarcoidosis. Data is sparse and conflicting, but indicate a beneficial 
effect on left ventricular function, reduced heart failure admissions and 
improved long-term clinical outcomes.86,87 Early diagnosis and initiation 
of therapy is important and titration of immunosuppression can be 
guided by FDG-PET.87–89 
Cardiac Infiltration
Heart failure with preserved ejection fraction remains poorly 
understood. However, recent evidence suggests that there is a subset 
of cardiomyopathies caused by cardiac amyloidosis in this patient 
group. Moreover, better understanding of these conditions is yielding 
disease-modifying treatments, placing a greater emphasis on early 
identification of these patients. 
The term amyloidosis describes a condition in which structurally 
unstable proteins misfold and aggregate to form fibrils that are 
deposited in organs and tissues. The misfolding and deposition of 
two proteins results in the vast majority of cardiac amyloidosis: 
immunoglobulin light chain (AL) and transthyretin (ATTR). Transthyretin 
can be further classified into wild type (ATTRwt) and that due to a 
mutation in the gene encoding transthyretin (ATTRm).90
Systemic Light-chain Amyloidosis
Systemic AL amyloidosis is a rare disease with a yearly incidence 
estimated at 3 per million in the UK and 8.9 per million, or 3,000 new 
cases per year, in the US.91,92 Approximately 30–50% of sufferers have 
cardiac involvement with 5% having isolated cardiac involvement. The 
average time from initial symptoms to diagnosis is 2 years, with nearly 
a third of patients requiring review by five physicians before receiving 
a diagnosis of amyloidosis.90 Cardiologists were consulted more than 
haematologists, nephrologists and oncologists, but rarely made the 
diagnosis.93 
Proteinuria or hepatomegaly in combination with heart failure should 
raise the suspicion of AL amyloidosis.94 Macroglossia and periorbital 
purpura are highly specific but present only in a minority of cases.90 
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Patients with significant cardiac involvement are unable to tolerate the 
preferred treatment of high-dose chemotherapy with autologous stem 
cell transplantation, emphasising the importance of early diagnosis.95 
Mortality at 6 months remains high at 24%, but is improving as patients 
are diagnosed earlier with less severe cardiac involvement.96 
Transthyretin Amyloidosis
ATTR amyloidosis is a multisystem disorder caused by aggregation of 
TTR amyloid fibrils.97–100 TTR cardiomyopathy (TTR-CM) is usually a late-
onset disease found in older men, with patients typically presenting 
aged 60 years or older.101 Symptoms include dyspnoea, fatigue and 
orthostatic hypotension. Signs of heart failure predominate in TTR-CM, 
often with a preserved ejection fraction. Clinical clues to its presence 
involve extra-cardiac amyloid deposition including carpal tunnel 
syndrome and peripheral neuropathy (Figure 2).102 
TTR-CM can be hereditary or non-hereditary. The non-hereditary form 
of the disease is caused by aggregation of ATTRwt. The hereditary 
form of the disease can be caused by more than 100 mutations in 
the TTR gene, of which at least 22 are associated predominantly with 
TTR-CM.103–5 The point mutation valine 122 to isoleucine (Val122Ile) is 
the most common TTR-CM variant, with a prevalence of about 3–4% in 
the African-American population. The proportion that develop clinical 
disease is much smaller.106–108
In patients with ATTRwt-CM, median survival ranges from 26–67 months 
from diagnosis and 72 months from symptom onset. Patients with 
Val122Ile ATTRm-CM have a median survival time from diagnosis 
ranging from 36 months to 43 months. Death in most patients 
with TTR-CM is from sudden death or progressive heart failure.109,110 
Recent data suggest that the prevalence of TTR-CM in older people 
has been under-appreciated. Autopsy data demonstrate that 25% 
of adults older than 80 years have TTR amyloid deposition in the 
myocardium, and 32% of patients aged 75 years or older with HFpEF 
demonstrate myocardial TTR amyloid deposits.111,112 Technetium-99m-
labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) 
scintigraphy reliably detects TTR-CM. Its use highlights a prevalence of 
13% of TTR-CM in patients admitted to hospital with HFpEF.113–116
Effective treatment may soon be available for TTR-CM. TTR is a 55-kD 
protein with a tetrameric structure that transports thyroxine and 
vitamin A complex. Amyloidogenesis occurs when the tetrameric 
structure dissociates resulting in the formation of intermediates that 
then deposit and polymerise as amyloid fibrils in the myocardium. 
The discovery of a stabilising polymorphism in the TTR gene has led 
to the discovery of tafamidis, a nonsteroidal anti-inflammatory drug 
benzoxazole derivative that adheres to the thyroxine binding sites 
and inhibits tetramer dissociation. Tafamadis has been shown to be 
superior to placebo in reducing the risk of death and cardiovascular-
related hospitalisations and it reduces the decline in functional 
capacity and quality of life.117 
Disorders of Metabolism
Anderson-Fabry Disease
Anderson-Fabry disease (AFD) is an X-linked recessive disorder 
caused by mutations in the GLA gene leading to reduced or absent 
activity of the enzyme alpha-galactosidase A. This deficiency leads to 
accumulation of glycosphingolipids in lysosomes in various tissues, 
including the heart. It results in myocardial remodelling and left 
ventricular hypertrophy and manifests as systolic and diastolic 
dysfunction, valvular abnormalities and conduction disease.
Presentation of AFD is typically in the first decade, with gastrointestinal 
symptoms, angiokeratomas or pain caused by a small-fibre neuropathy. 
However, up to 10% of patients can present with cardiac involvement, 
highlighting the importance of adopting a low-threshold of suspicion, 
particularly for patients with left ventricular hypertrophy.118,119 
Figure 2: A Case of Worsening Breathlessness
 A 72-year-old African-Caribbean man presented with a 6-month history of worsening breathlessness. The only past medical history of note was bilateral carpal tunnel decompression. 
Blood tests demonstrated elevated brain natriuretic peptide levels at 4430 ng/l and evidence of chronic kidney disease with an estimated glomerular filtration rate of 38 ml/min. A 12-lead 
ECG showed sinus rhythm with a prolonged PR interval, broadening QRS complex and left axis deviation. Echocardiography highlighted a bright, speckled myocardium with left ventricular 
hypertrophy and reduced longitudinal strain with an apical-sparing pattern. Cardiac MRI demonstrated significant, diffuse late gadolinium enhancement. Technetium-99m-labelled 
3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy showed Perugini grade 2 cardiac uptake consistent with cardiac transthyretin amyloidosis. There was no uptake on serum amyloid 
P scintigraphy and there was no underlying plasma cell dyscrasia. Transthyretin gene sequencing confirmed a wild-type gene and the patient is due to start  treatment with tafamidis.
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As many as 10% of patients with AFD develop severe heart failure 
(defined by New York Heart Association classification ≥3) and cardiac 
disease is the major cause of death, accounting for 38% of all-cause 
mortality.120,121 Enzyme replacement therapy is the standard treatment 
for AFD, aiming to compensate for reduced endogenous alpha-
galactosidase activity with treatment leading to improved cardiac 
outcomes. It is readily apparent that enzyme replacement therapy 
started at a younger age leads to better outcomes illustrating the 
importance of identifying these patients at an early stage in the 
disease process.122–125
Iron-overload Cardiomyopathy
Iron-overload cardiomyopathy (IOC) should be considered in any 
patient with unexplained heart failure. It can be caused by a primary 
haemochromatosis where iron accumulation occurs through increased 
gastrointestinal iron absorption, or by secondary iron-overload, most 
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Figure 3: Flow Diagram Illustrating a Proposed Diagnostic Algorithm for Patients Presenting to Heart Failure Clinic 
*Serology to include full blood count, urea and electrolytes, liver function tests, thyroid function tests, creatine kinase and brain natriuretic peptide. †Infiltrative pattern on echocardiography 
may include a bright, speckled myocardium with left ventricular hypertrophy and reduced global longitudinal strain with apical sparing. 99mTc-DPD = technetium-99m-labelled 
3,3-diphosphono-1,2-propanodicarboxylic acid; AFD = Anderson-Fabry disease; AL amyloidosis = primary light chain amyloidosis; CTCA = CT coronary angiogram; CMR = cardiac MRI;  
CXR = chest X-ray; FDG-PET = fluorodeoxyglucose PET; GSD = glycogen storage disorder; HTN = hypertension; IHD = ischaemic heart disease; PPM = permanent pacemaker; SAP = serum 
amyloid P; SCD = sudden cardiac death; TTR amyloidosis = transthyretin amyloidosis.
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commonly due to a high frequency of blood transfusions.94 The 
pathophysiology is complex and not simply related to myocardial 
iron accumulation with immunoinflammatory, molecular and genetic 
factors implicated.126
The early stages of IOC are characterised by left ventricular diastolic 
dysfunction with restrictive physiology.127,128 Progression can lead to a 
dilated phenotype with biventricular dilatation and systolic dysfunction 
or to a restrictive phenotype with preservation of LVEF, pulmonary 
hypertension and right ventricular dilatation.129–131 It can also present 
with acute heart failure.132 
Serum ferritin and transferrin saturation should be included in 
the initial investigation of any patient with newly diagnosed heart 
failure.11 Echocardiography may help with ventricular assessment 
and an estimation of pulmonary pressures, however cardiac MRI 
with T2* is able to quantitatively assess myocardial iron content and 
predict progression to heart failure within one year.133,134 Identification 
of patients with an IOC is imperative as both iron removal using 
phlebotomy and chelation therapy have been shown to improve 
heart function.135–138 With the introduction of chelation therapies and 
MRI with T2* there has been a significant improvement in mortality 
rates, predominantly driven by reductions in death due to cardiac iron 
overload.139 Early initiation of therapy is therefore crucial. 
Improving the Detection of Actionable 
Diagnoses
The definition of heart failure rests on a constellation of typical 
symptoms and an underlying structural or functional cardiac 
abnormality leading to deranged cardiac physiology. This definition 
captures a patient cohort that, historically, have been managed with 
a simple treatment algorithm; a ‘one-size-fits-all’ approach. A third 
of these patients are categorised as suffering an idiopathic DCM. We 
contend that rare but readily identifiable aetiologies reside within 
this group and, more importantly, that they are actionable diagnoses 
leading to targeted therapies.
The diagnosis of rare disease among people with heart failure may be 
challenging, particularly where resources are constrained and access 
to specialist cardiac investigations limited. Diagnoses are often made 
following a conspicuous event such as unexplained syncope or sudden 
death in a relative. On other occasions, diagnoses are delayed and are 
reached only with retrospective recognition of atypical features.
Elucidating the rarer causes of heart failure may need specialised 
knowledge or access to investigations such as genetic testing. We 
argue, however, that a diagnostic ‘red flag’ approach to clinical 
assessment in the heart failure clinic, combined with routinely 
available tests, can act as an initial filter to more readily identify 
uncommon disease. This approach begins with a thorough, 
hypothesis-driven clinical and family history and incorporates basic 
serology, an ECG and baseline imaging (Figure 3).18 Ischaemic, 
valvular and hypertensive heart disease should be managed as per 
guidelines.140–142 Acquired and reversible causes of heart failure such 
as alcohol excess and prolonged tachycardia are readily identifiable 
with thorough clinical assessment and routine investigations.11 Cardio-
oncology is a growing sub-specialty, with increasing recognition of 
the cardiotoxic effects of both established chemotherapy agents 
and newer immunotherapies and targeted therapies. Left ventricular 
dysfunction and heart failure are relatively common and serious side-
effects of cancer treatment.143 
After preliminary assessment, patients without an obvious cause for 
heart failure can be directed to one of three investigative streams: 
genetic, inflammatory or infiltrative/metabolic.24,144,145 Awareness of dual 
pathologies is important as, for example, hypertension may coexist 
with infiltrative disease in a patient with left ventricular hypertrophy.146
Precision Medicine in Heart Failure
NHS England embraces the concept of personalised, precision medicine 
recognising that “complex diseases should no longer be considered a 
single entity” and that “different subtypes of patients within a given 
condition can be identified and treatment can be tailored to the 
underlying cause”. It urges more precise diagnoses and emphasises 
the usefulness of genomic medicine.147
The field of oncology offers a paradigm of the precision medicine 
approach. Where previously cytotoxic treatments with severe side-
effects were the norm, we now see therapies designed to precisely 
target cancer cells. This is chiefly through two methods: pathway-
targeted therapy and immunotherapy.148 These approaches seem 
particularly well-suited to future treatment of inflammatory and 
infiltrative heart disease.
The one-size-fits-all approach continues to prevail in the modern 
management of heart failure. This article highlights the diverse 
pathogeneses of the heart failure syndrome and how it could benefit 
from a precision medicine approach. The underlying biology of the 
conditions outlined is increasingly well described, resulting in the 
development of new therapies that offer significant clinical benefit, 
particularly when instituted at an early stage in the disease process. 
Furthermore, these conditions, traditionally thought of as rare, are 
more common than first thought and, in combination, account for a 
significant burden of disease. 
We offer a diagnostic algorithm that aims to co-opt principles of 
precision medicine into heart failure clinics. If adopted, we hypothesise 
that the population prevalence of idiopathic DCM would decline as 
patients are given aetiology-specific diagnoses with accompanying 
disease-modifying treatments. 
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